Written by: Andy Russell, Vice President, Growth & Product Strategy at RxE2The San Diego Signal: An Industry Carrying a Heavy Load There was a moment coming out of GCSG this year where something started to feel different. Not because we suddenly discovered new problems. We didn’t. If anything, the industry showed just how well it…
The recent 2026 U.S. Annual Conference of the Global Clinical Supplies Group in San Diego felt different than previous years. In the past, these gatherings often focused on the promise of distant technologies or abstract innovations. However, the tone this year was grounded in a heavy sense of pragmatism. Leaders from the largest pharmaceutical organizations…
On April 21st, 2026, RxE2 hosted a landmark virtual fireside chat between CEO Gerald Finken and Craig Lipset, Co-Founder of the Decentralized Trials & Research Alliance (DTRA). The conversation moved beyond the buzzwords of virtual trials to address the fundamental architecture of how we develop medicines. The Crisis of Access: Three Inputs, One Major Bottleneck…
Introduction Following our deep dive into the mechanics of clinical trials with Austin Tull, we continue our series aimed at demystifying the evolving landscape of clinical research. While the “what” of clinical trials is rooted in safety and efficacy, the “how” is undergoing a radical transformation. This shift is known as Decentralized Clinical Trials (DCT),…
Introduction In the highly regulated ecosystem of clinical research, innovation often feels slow, confined by complex protocols and centralized infrastructures. Yet, a quiet revolution is taking place, driven by technology that is fundamentally shifting where and how clinical trials are conducted. At the forefront of this movement is RxE2, and guiding the technological architecture that…
Pharmacists hold a unique and powerful position in healthcare, not only as medication experts but also as some of the most trusted professionals that patients encounter regularly. Trust is an essential element in healthcare because it influences how patients follow treatments, share information, and engage in health programs such as clinical trials. While doctors and…
Introduction: what is a hybrid clinical trial? A hybrid clinical trial is a study design that incorporates elements of traditional in-person clinical trials with decentralized clinical trial (DCT) components. In a hybrid trial, participants may still be required to attend physical clinical sites for certain procedures. However, other study activities can be conducted remotely by…
Introduction In today’s fast-paced world, pharmacies play a vital role in granting people access to fundamental medicines and health services. There are two primary categories of pharmacies: independent community pharmacies and chain pharmacies. Despite serving as crucial healthcare facilities, they differ greatly in treating patients, offering customized services, and incorporating with the community. In this…
Diversity Now, the first protocol to achieve diversity in clinical trials according to the FDA guidelines for Race and Ethnicity Diversity Plans This plan provides a pharmacist-centered approach for compliance with Section V Categories 4 and 5 of the US Food and Drug Administration’s industry guidance (hereinafter “FDA Guidance”) for developing the required Race and…
Diversity in Clinical Trials – Background The Federal Drug Administration (FDA) issued non-compulsory guidance on clinical trial diversity to encourage diverse populations in clinical trials and improve the applicability of clinical trial results. The guidance recommends diverse clinical trial populations to better understand the safety and effectiveness of medical products across race, ethnicity, and gender.…